1. Savara faces investigation over potential federal securities law violations. 2. FDA issued a refusal-to-file letter for MOLBREEVI on May 27, 2025. 3. Guggenheim reduces price target after FDA announcement, signaling commercialization delays. 4. Savara's stock dropped 31.7% following negative news on May 27, 2025.
The negative news led to a significant stock price drop, historically indicating investor concern.
The investigation indicates potential legal troubles that could affect investor confidence and stock value.
Initial reactions are often immediate, but ongoing developments may stabilize price dynamics.
The Law Offices of Frank R. Cruz announces an investigation of Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) on behalf of investors concerning the Company's possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON SAVARA (SVRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On May 27, 2025, Savara issued a press release announcing that the U.S. Food and Drug Administration had issued a refusal-to-file letter for the Company's Biologics License Application for MOLBREEVI, determining that the submission was not sufficiently complete and requesting additional Chemistry, Manufacturing, and Controls data. That same day, Guggenheim published a report lowering its price target for Savara and warning of potential delays in commercialization and the likelihood of additional capital raises.
On this news, Savara's stock price fell $0.90, or 31.7%, to close at $1.94 per share on May 27, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Savara securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909075678/en/
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com